ExpansionApr 29, 2026, 04:54 PM
CTOR Ships First LYMPHIR™ International Order to Europe
AI Summary
Citius Oncology, Inc. announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners. This marks a strategic milestone in expanding international patient access to the therapy via Named Patient Programs, complementing the ongoing U.S. commercial launch. The company continues to see encouraging adoption in the U.S. market, which is estimated to exceed $400 million and is underserved by existing therapies.
Key Highlights
- CITIUS ONCOLOGY ships initial LYMPHIR™ order to Europe via regional distribution partners.
- LYMPHIR will be available to eligible patients through Named Patient Programs (NPPs).
- This expands international patient access to LYMPHIR beyond the United States.
- Company continues to execute U.S. commercial launch strategy with encouraging adoption.
- LYMPHIR was approved by US FDA in August 2024 for Stage I-III r/r CTCL.
- U.S. commercial launch of LYMPHIR occurred in December 2025.
- Estimated initial U.S. market for LYMPHIR currently exceeds $400 million.